Thrive Wealth Management LLC Sells 1,900 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Thrive Wealth Management LLC reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 24.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,875 shares of the biopharmaceutical company’s stock after selling 1,900 shares during the period. Thrive Wealth Management LLC’s holdings in Gilead Sciences were worth $430,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Etesian Wealth Advisors Inc. grew its holdings in shares of Gilead Sciences by 0.7% in the fourth quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock valued at $1,486,000 after acquiring an additional 128 shares in the last quarter. Financial Counselors Inc. raised its stake in shares of Gilead Sciences by 1.5% during the 4th quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock worth $718,000 after purchasing an additional 128 shares during the period. Revolve Wealth Partners LLC boosted its holdings in shares of Gilead Sciences by 3.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock worth $292,000 after buying an additional 130 shares during the last quarter. Steph & Co. grew its position in Gilead Sciences by 1.9% during the fourth quarter. Steph & Co. now owns 7,548 shares of the biopharmaceutical company’s stock valued at $611,000 after buying an additional 142 shares during the period. Finally, First Affirmative Financial Network increased its holdings in Gilead Sciences by 3.5% during the first quarter. First Affirmative Financial Network now owns 4,342 shares of the biopharmaceutical company’s stock worth $318,000 after buying an additional 147 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently commented on GILD. StockNews.com raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 27th. Oppenheimer reaffirmed an “outperform” rating and issued a $105.00 price target on shares of Gilead Sciences in a report on Friday, April 19th. Maxim Group decreased their price objective on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Wednesday, May 1st. Wells Fargo & Company cut their target price on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research note on Monday, March 4th. Finally, UBS Group lowered their price target on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Twelve equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $83.47.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the sale, the insider now owns 96,304 shares in the company, valued at $7,026,339.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD traded down $0.48 during trading hours on Thursday, reaching $68.83. 6,859,832 shares of the stock traded hands, compared to its average volume of 7,638,361. The company’s 50-day simple moving average is $65.89 and its two-hundred day simple moving average is $72.75. The company has a market capitalization of $85.75 billion, a P/E ratio of 192.25, a price-to-earnings-growth ratio of 2.96 and a beta of 0.20. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $87.86. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, topping the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The firm had revenue of $6.69 billion for the quarter, compared to the consensus estimate of $6.36 billion. During the same period last year, the firm posted $1.37 earnings per share. The business’s revenue was up 5.3% compared to the same quarter last year. Equities research analysts forecast that Gilead Sciences, Inc. will post 3.75 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be paid a dividend of $0.77 per share. The ex-dividend date is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.47%. Gilead Sciences’s dividend payout ratio (DPR) is currently 855.56%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.